abstract: Utilizing epigenetic (DNA methylation) differences to differentiate between maternal peripheral blood (PBL) and fetal (placental) DNA has been a promising strategy for non-invasive prenatal testing (NIPT). However, the differentially methylated regions (DMRs) have yet to be fully ascertained. In the present study, we performed genome-wide comparative methylome analysis between maternal PBL and placental DNA from pregnancies of first trimester by methylated DNA immunoprecipitation-sequencing (MeDIP-Seq) and Infinium HumanMethylation450 BeadChip assays. A total of 36 931 DMRs and 45 804 differentially methylated sites (DMSs) covering the whole genome, exclusive of the Y chromosome, were identified via MeDIP-Seq and Infinium 450k array, respectively, of which 3759 sites in 2188 regions were confirmed by both methods. Not only did we find the previously reported potential fetal DNA markers in our identified DMRs/DMSs but also we verified fully the identified DMRs/DMSs in the validation round by MassARRAY EpiTYPER. The screened potential fetal DNA markers may be used for NIPT on aneuploidies and other chromosomal diseases, such as cri du chat syndrome and velo-cardio-facial syndrome. In addition, these potential markers may have application in the early diagnosis of placental dysfunction, such as pre-eclampsia.
Introduction
Conventional invasive procedures, such as amniocentesis and chorionic villus sampling, are recommended for high-risk pregnancies. However, these invasive techniques raise the risk of miscarriage and fetal abnormality and bring pressure to the mothers as well. The discovery of cell-free fetal DNA (cffDNA) in the maternal circulation during pregnancy (Lo et al., 1997) opened a new perspective for the development of non-invasive prenatal testing (NIPT). Numerous studies have demonstrated that cffDNA originated from cyto-trophoblastic and syncytiotrophoblastic cells of the placenta (Flori et al., 2004; Masuzaki et al., 2004) . Compared with the number of fetal nucleated cells, cffDNA in maternal peripheral blood (PBL) is present at a relatively high level (mean of 25 genome equivalents per milliliter) (Lun et al., 2008a) . To date, the diagnostic implementations of circulating fetal DNA analysis in clinical practice include fetal sex determination (Costa et al., 2001; Rijnders et al., 2001; Honda et al., 2002) , fetal rhesus D blood group status assessment (Lo et al., 1998; Sedrak et al., 2011) , fetal chromosomal aneuploidy detection (Lo et al., 1999 (Lo et al., , 2007 Chiu et al., 2008; Papageorgiou et al., 2011; Sehnert et al., 2011) and fetal single gene disorder exclusion/ detection (Saito et al., 2000; Lun et al., 2008b) . However, the relatively low concentration of cffDNA compared with the larger background maternal DNA and lack of universal fetal-specific DNA markers have limited its widespread clinical application.
Differences in the pattern of tissue-specific DNA methylation can be used to differentiate between maternal and placental DNA. SERPINB5 (maspin) on chromosome 18, the first universal fetal DNA marker in maternal plasma with differential methylation patterns between maternal PBL and placental DNA, provides a novel approach for distinguishing fetal DNA from the background maternal DNA or the enrichment of † These two authors contributed equally to this work. fetal DNA (Chim et al., 2005) . The significant implications of this finding paved the way for identifying additional universal markers for fetal DNA, RASSF1A gene on chromosome 3 (Chan et al., 2006) and genes on chromosome 21 (Chim et al., 2008) were identified afterwards. Papageorgiou et al. (2009) identified .2000 differentially methylated regions (DMRs) between maternal and placental DNA using methylation DNA immunoprecipitation coupled with tiling oligonucleotide array analysis specific for chromosomes 21, 18, 13, X and Y. Additionally, they proposed a fetal-specific methylation ratio approach based on the above DMRs with hypermethylation in placental DNA on chromosome 21 and provided 100% sensitivity and 100% specificity in the non-invasive diagnosis of Down syndrome (Papageorgiou et al., 2011) .
Such significant clinical reports prompted us to investigate potential fetal DNA specific markers in a genome-wide scale. In this study, we have assessed and compared the methylation patterns between maternal PBL DNA and placental DNA in the first trimester (11 -14 weeks) to search for DMRs. DNA methylome profiling was performed in two complementary platforms including methylated DNA immunoprecipitation sequencing (MeDIP-Seq) and Infinium HumanMethylation450 BeadChip assays.
Materials and Methods

Pregnancies and clinical samples
Placentas and maternal PBL samples were collected from women who underwent induced labor (n ¼ 14). All women enrolled in this study are from the Han Chinese population and are all in the first trimester (11-14 weeks). All participants signed written statements of informed consent. For each participant, 5 ml of maternal PBL was collected before the obstetrics procedures; small pieces of placenta were dissected from the fetal side. All clinical samples were stored frozen at 2808C before use. The study protocols were reviewed and approved by Fudan University Ethical Committee.
DNA preparation and bisulfite conversion
Genomic DNA was isolated from placentas and maternal PBL using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) or QIAamp Blood DNA Mini Kit (Qiagen) according to the manufacturer's protocol. An RNase step was included during DNA isolation to avoid the contamination by RNA. DNAs for the 450k assays and quantitative DNA methylation analysis by MassARRAY EpiTYPER were bisulfite converted using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the recommended protocols. DNA concentration and purity were analyzed by NanoDrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).
MeDIP-Seq
Maternal PBL and placenta samples from pregnancies with a male fetus were included in the MeDIP-Seq analysis. More information about the clinical samples used is summarized in Supplementary data, Table SI. DNA (5 mg) from maternal PBL or placenta was sheared to fragments between 100 and 500 bp by sonication. Sonicated DNA was then subjected to end-repair and adaptor ligation according to the protocol supplied with the Pair-end DNA Sample Prep Kit (Illumina). After the denaturation of double-strand DNA, DNA enrichment was performed with 5 mC antibodies (Diagenod). Following size selection (between 220 and 320 bp) and library quality control, suitable libraries were sequenced as paired ends on a HiSeq 2000 Sequencing System (Illumina, CA, USA). The sequencing reads which passed trimming, filtering and normalization were aligned to human genome reference sequences (NCBI, build36) by SOAP2 with no .2 bp mismatches. The uniquely mapped reads were used for the following analysis. Peak scan was performed using a Model-based Analysis of ChIP-Seq (MACS, version MACS1.4.0) (Zhang et al., 2008) , and the identified peaks were then used to compare the differences between maternal PBL and placenta.
Infinium HumanMethylation450 BeadChip assay
Global DNA methylation profiling of 10 pairs of maternal PBL and placental DNA from women who experienced induced labor, including 7 male fetuses and 3 female fetuses, was conducted on Infinium HumanMethylation450 BeadChip Arrays (450k, Illumina). The Infinium methylation assay was performed according to Infinium Assay Methylation Protocol Guide Rev. C (November 2010). Raw data and microarray images obtained by scanning the chips using HiScan (Illumina) were processed with the Methylation Module of GenomeStudio software (Illumina), and a b value of 0 (unmethylated) to 1 (completely methylated) was chosen to output for each CpG site, representing the methylation level. The CpG sites with missing b values were removed, and the CpGs with Db ≥ 0.4 were applied as candidates. The Wilcoxon rank-sum test was employed to calculate the P value.
Validation of the differentially methylated regions/sites with MassARRAY EpiTYPER
Quantitative DNA methylation analysis was performed using the MassArray EpiTYPER (Sequenom, San Diego, CA, USA). For MeDIP-Seq validation, 13 maternal PBL-placenta pairs were used. To validate 450k array data, we first replicated the methylation patterns of candidate CpGs in the 10 bloodplacenta pairs used in the array and then compared the methylation level of candidates in another 4 available blood -placenta pairs. Several DMRs and differentially methylated sites (DMSs) with significant methylation differences between maternal PBL and placentas were selected as candidates in the validation round. Target-specific primers were designed using the online software Epidesigner (http://www.epidesigner.com/), and a detailed list of primers is shown in Supplementary data, Table SII. The quantitative methylation data for each CpG site, or aggregates of multiple CpG sites, obtained were analyzed with the EpiTYPER software (Sequenom). Statistical analyses were performed using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA). Statistical data were presented as mean + SD. A P value of ,0.05 was considered as statistically significant.
Results
High-throughput sequencing analysis by MeDIP-Seq
The methylomic profiling of maternal PBL and placenta from a pregnant woman with a male fetus was generated by MeDIP-Seq. In total, 40 million paired-end reads (3.52 Gb, with a read length of 44 bp × 2) for each sample were generated. The sequencing reads and mapping rate generated by MeDIP-Seq are shown in Supplementary data, Table SIII. All the uniquely mapped reads were scanned in 10 kb tiled genome windows for each chromosome to calculate the sequencing depth of reads in each window, in which the reads were normalized based on the formula: (the number of reads in each 10 kb window × 1 000 000)/uniquely mapped reads. The enrichment of normalized reads on each chromosome is shown in Supplementary data, Fig. S1 .
By using MACS, 229 789 and 230 575 peaks were identified from the MeDIP-Seq data of placenta and maternal PBL, respectively (Supplementary data, Table SIV Regions exhibiting at least a 4-fold change in methylation and with a P value of ,0.01 were determined as significantly different. A total of 22 693 hypermethylated regions and 14 238 hypomethylated regions were screened in placenta compared with the matched maternal PBL. We further analyzed the distribution of DMRs on chromosomes and observed that the DMRs were present in each chromosome. Regions on chromosome Y were not within the scope of this analysis. Most DMRs were hypermethylated on the autosomes or hypomethylated on the X chromosome in placenta (Table I ). The DMRs identified by MeDIP-Seq are shown in Supplementary data, Table SIV .
Global methylation landscapes by Infinium HumanMethylation450 Beadchip assay
We assessed comprehensive DNA methylation profiles with the 450k array in matched maternal PBL-placentas from 10 women who experienced induced labor. Quality control of the methylation analysis by 450k array was performed (Supplementary data, Fig. S6 ), demonstrating a complete distinction between maternal PBL and placentas at all CpG sites. In total, 8756 CpG sites with a missing b value were filtered out of the analysis. Ultimately, 46 182 CpGs with absolute methylation difference Db ≥ 0.4 and P ≤ 1 × 10 27 were reserved to be analyzed further, which mapped across all chromosomes and indicated uneven distributions across the whole chromosomes (chromosome Y was not within the scope of our analysis). Our results showed that the number of hypomethylated CpG sites in placentas was significantly more than the hypermethylated ones in each chromosome, with a total of 36 411 hypomethylated and 9393 hypermethylated CpG sites in placentas (Table II) . The detailed information on the DMSs mentioned above is provided in Supplementary data, Fetal DNA markers for non-invasive prenatal testing
We subsequently performed overlapping analysis of the sites/regions identified by MeDIP-Seq and the 450k array, and observed 3759 CpG sites in 2188 genomic regions in both approaches.
DMRs with MassARRAY EpiTYPER
We firstly compared our results with previous publications, including SERPINB5, RASSF1A and DMRs identified by Papageorgiou et al. (2009) . As expected, methylation patterns of RASSF1A (chr3:50350951-50352251), RAX (chr18:55090279-55090959), AGPAT3 (chr21: 44160993-44161543), C21orf25 (chr21:42189235-42189849; chr21:42355366-42355908; chr21:42357141-42357401) and HUNK (chr21:32268787-32269137; chr21:44079218-44079733) are consistent with our MeDIP-Seq analysis in comparison with previously reported findings (Chan et al., 2006; Papageorgiou et al., 2009) (Supplementary data, Fig. S7 ). Similar methylation patterns of SERPINB5 promoter regions, RASSF1A, RAX and AGPAT3, were also found in our 450k array compared with previous results (Chim et al., 2005; Chan et al., 2006; Papageorgiou et al., 2009 ) (Supplementary data, Fig. S8) .
We next performed the validation round for the defined DMRs/DMSs in our available clinical samples. For MeDIP-Seq, 10 DMRs with a large difference in normalized sequencing reads and fold enrichments were selected as targets. According to our verification, the direction of validation round was consistent with that in MeDIP-Seq data (Fig. 1A) . The normalized sequencing reads and fold enrichments generated by MeDIP-Seq, and the average methylation levels generated by MassAR-RAY EpiTYPER of candidate DMRs, are shown in Table III . For 450k array, the b value could provide the exact methylation level of the CpG sites. CpG sites on chromosome 21 and other chromosomes with large loci difference (Db) between maternal PBL and placentas were selected as candidates to perform quantitative analysis. The methylation level in the replication round, including the 10 blood -placenta pairs used in the array, showed consistency with the b value provided by the array. Furthermore, the methylation levels quantified in another four new blood -placenta pairs were also highly consistent with the replication round (Fig. 1B) . Considering the consistency between the replication and validation round, we did not separate the two groups of samples in the following analysis. We further conducted a comparison of methylation levels of target CpGs provided by 450k array, the target CpGs and the whole tested regions provided by MassARRAY EpiTYPER (Table IV) 
Potential fetal DNA methylation markers for early screening for disorders
To identify suitable biomarkers for non-invasive prenatal diagnosis of disorders is our ultimate goal in the present study. It is well known that the maternal DNA accounts for .90% of the total plasma DNA in pregnancy, especially in the first trimester. Therefore, we were inclined to choose regions that were almost completely methylated or ummethylated in maternal PBL. In this case, fetal DNA can be largely enriched in the unmethylated or the methylated DNA fragments. Considering that MeDIP-Seq provides the relative quantitative methylation level, DMRs that were hypermethylated in placental DNA and nearly unmethylated in maternal PBL were selected as potential fetal DNA markers. The specific selection criteria are as follows: the ratio of normalized reads between placenta and maternal PBL ≥ 3, which indicates that The methylation level of ITGB2 and BRDT quantified in 14 maternal PBL-placenta pairs. The 10 placentas and the corresponding maternal PBL used in the array were regarded as the replication round (placenta-Re, PBL-Re). Four blood -placenta pairs were in the validation round (placenta-Va, PBL-Va). *The CpG site in the region was the corresponding target CpG in the Infinium 450k array. All data are presented as mean + SD. PBL, peripheral blood.
Fetal DNA markers for non-invasive prenatal testing these loci are hypermethylated in placental tissue compared with maternal PBL; and the ratio of peak length to the number of reads of maternal PBL ≥ 60, which indicates that these loci are nearly unmethylated in maternal PBL because few DNA fragments were captured to sequence. Tables SVII -SIX) and of these, 6 DMSs in 2 DMRs on chromosome 13, 3 DMSs in 3 DMRs on chromosome 18 and 4 DMSs in 3 DMRs on chromosome 21 were confirmed by both platforms (Table V) . Considering the X chromosome inactivation in female, a consistent methylation pattern in placenta of male and female fetuses was an additional screening criterion for potential makers on chromosome X. There were 11 target CpGs representing 11 DMRs being selected (Supplementary data, Table SX ). Meanwhile, we identified 24 DMRs in MeDIP-Seq data and 21 target CpGs in 450k array data (Table V and Supplementary data, Table SXI) that were located on chr5: 3.1M-31.9M, which is associated with cri du chat syndrome (Zhang et al., 2005) . Notably, there are 9 DMRs in MeDIP-Seq data and 10 target CpGs in 450k array (Table V and Supplementary data, Table SXII ) located on the genomic region chr22:17374949-19782754 that is related to velo-cardio-facial syndrome (VCFS), a relatively common microdeletion disease (Carlson et al., 1997) .
The universal fetal DNA markers that could be similarly detected in plasma of pregnancies with male or female fetuses are useful to measure the fetal DNA concentration and can serve as an internal control for detecting chromosomal diseases. The perfect universal fetal DNA marker should show high homogeneity between individual fetuses and be able to exclude maternal DNA easily. We screened the potential in the 450k array data. The screening criteria are as follows: the standard error of the b value in both maternal PBL and placental tissue was ,0.03; the methylation level in each blood sample was ,0.05 or .0.90; and DMSs on chromosomes 13, 18 and 21, SNPs or common copy number variations are excluded. A total of 58 DMSs that could serve as potential universal fetal DNA markers were available (Table V and Supplementary data, Table SXIII ).
Discussion
Strategies exploiting the differences in DNA methylation between maternal and placental DNA to distinguish fetal DNA from maternal DNA in order to perform non-invasive prenatal tests have been a promising advance in prenatal care. There have been several studies reporting a search for DMRs between maternal and placental DNA either in a limited number of genes (Chim et al., 2005; Yuen et al., 2010; Zhao et al., 2011; Xiang et al., 2013) bright spot of the present study is that we identified substantial DMRs between placentas and paired maternal PBL on a genome-wide scale, using two complementary platforms. Compared with previous reports, the present methylation profiling of maternal PBL and placentas provide high resolution: the screened potential fetal DNA markers were all ,1 kb in length, while most DMRs span 10 k bp or longer in a previous study (Papageorgiou et al., 2009) . Studies have shown that the methylation level within adjacent regions shared the same methylation status (Eckhardt et al., 2006) , which was also evident in our 450k array validation results, with a similar regional methylation level around the target CpGs (Table IV) . Methylation profiling with high resolution could not only provide a convenient method for identifying NIPT markers for chromosomal aneuploidies, such as trisomy 21 (Papageorgiou et al., 2011) , but also have potential in NIPT for diseases associated with submicroscopic copy number mutations. For example, we have identified 9 DMRs in MeDIP-Seq data and 10 target CpGs in 450k array within an 3 Mb genomic region for VCFS. In the present study, three methods were employed to perform the quantitative DNA methylation analysis. We preferred to choose DMRs identified by MeDIP-Seq and 450k array which were validated well by MassARRAY EpiTYPER in order to reduce the inter-experimental epigenetic variability. The DMRs between placentas and paired maternal PBL provide potential markers to enrich the fetal DNA in maternal cell-free DNA (cfDNA). For example, a cfDNA sample containing 5% fetal DNA from a trisomy 21 fetus should exhibit only a 2.5% increase in the proportion of DNA fragments from chromosome 21 when compared with a normal fetus. For the DMRs in chromosome 21 that are 5% methylated in maternal DNA and 50% methylated in fetal DNA, there is 34% methylated DNA in the cfDNA sample from a normal fetus, with a 17% increase in that from a trisomy 21 fetus, 7 times greater than that in the total cfDNA. Therefore, the methods using information from DMRs may help to reduce costs and improve the sensitivity and specificity for NIPT. Using sequence capture approaches followed by bisulfite conversion and adaptor-mediated PCR amplification, the DNA fragments that are methylated or unmethylated in these DMRs from maternal plasma can be quantified simultaneously with parallel sequencing platforms, and such analysis may be helpful in the diagnosis of multiple chromosomal diseases as well as aneuploidies. This kind of test may have a similar or even lower cost compared with current sequencing methods for chromosomal aneuploidies since only the DNA fragments of certain methylation status in the DMRs need to be sequenced. The universal fetal DNA markers located on chromosomal regions without structural variations can be used for normalizing fetal DNA concentrations in diagnosing chromosomal diseases. Moreover, these universal makers are also useful for monitoring and predicting pregnancy-related conditions associated with aberrant fetal DNA concentrations, such as preeclampsia (Shimada et al., 2004; Illanes et al., 2009) .
Although substantial DMRs were identified by use of MeDIP-Seq and 450k array, overlapping analysis of the two approaches indicated a relatively low percentage, suggesting the heterogeneity of the two DNA methylation platforms. MeDIP-Seq could provide genome-wide coverage and has been used to generate the methylation profile of many tissues (Pomraning et al., 2009; Kerkel et al., 2010; Laird, 2010) . Our results agreed with previous reports that MeDIP-Seq was more sensitive to regions with highly methylated, high-CpG densities (Li et al., 2010) . Hence, there is a capture-dependent coverage bias in DNA methylation quantification especially in regions with low methylation and low CpG densities with MeDIP-Seq. The actual resolution of MeDIP-Seq is 150-200 bp, and it gives the relative methylation levels according to the fold change enrichments between pairs of samples. The 450k array is a high-throughput screening tool that can provide efficient, robust and affordable genome-wide methylation profiling at single-base resolution. It has been applied in a wide range of research areas, such as identification of tissue-specific DMRs (Slieker et al., 2013) and identification of potential markers for early cancer screening (Cahill et al., 2013; Heyn et al., 2013) . The quantitative accuracy of this platform has been shown in recent studies (Bibikova et al., 2011; Dedeurwaerder et al., 2011) 
